Kazuyoshi Kawakami
Overview
Explore the profile of Kazuyoshi Kawakami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
3259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashimoto K, Yokokawa T, Nonomiya Y, Shibata N, Soejima A, Kobayashi K, et al.
Oncology
. 2025 Mar;
:1-23.
PMID: 40064150
Introduction: Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study...
2.
Yoshida N, Imai S, Kawakami K, Yokokawa T, Nakamura M, Aoyama T, et al.
J Cancer
. 2025 Feb;
16(5):1413-1419.
PMID: 39991570
Many studies have identified risk factors for neutropenia associated with various chemotherapies, including gemcitabine plus nab-paclitaxel (GnP). However, few studies have focused on the delayed recovery from neutropenia, which frequently...
3.
Hatori M, Fukuoka S, Kimura S, Kawakami K, Yamaguchi K, Yamaguchi M
Oncology
. 2024 Dec;
1-9.
PMID: 39647476
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanzapine. However, olanzapine is contraindicated in patients with preexisting diabetes mellitus...
4.
Asano M, Shimizu H, Yokokawa T, Suzuki W, Kawakami K, Kobayashi K, et al.
Gan To Kagaku Ryoho
. 2024 Oct;
51(9):913-918.
PMID: 39462626
Perioperative fluorouracil, epirubicin and cyclophosphamide(FEC)therapy is a standard treatment for breast cancer. However, more than 20% of patients with breast cancer who undergo FEC therapy experience febrile neutropenia(FN), for which...
5.
Tomomatsu T, Shimizu H, Yokokawa T, Fukada I, Kawakami K, Kobayashi K, et al.
Yakugaku Zasshi
. 2024 Sep;
144(9):897-904.
PMID: 39218657
This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this...
6.
Kitai Y, Watanabe O, Ohmiya S, Kisu T, Ota R, Kawakami K, et al.
Sci Rep
. 2024 May;
14(1):11823.
PMID: 38783052
Our previous findings indicated that many respiratory syncytial virus (RSV) isolates are unstable at 4 °C compared to 20 °C. Some of the strains completely lose infectivity after 24 h...
7.
Miyahara A, Umeki A, Sato K, Nomura T, Yamamoto H, Miyasaka T, et al.
Infect Immun
. 2024 May;
92(6):e0002424.
PMID: 38700335
is a yeast-type fungus that causes fatal meningoencephalitis in immunocompromised patients and evades phagocytic cell elimination through an escape mechanism. Memory T (Tm) cells play a central role in preventing...
8.
Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, et al.
Cancer
. 2024 Apr;
130(17):2988-2999.
PMID: 38682652
Background: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs...
9.
Kamii Y, Hayashizaki K, Kanno T, Chiba A, Ikegami T, Saito M, et al.
Proc Natl Acad Sci U S A
. 2024 Feb;
121(9):e2313964121.
PMID: 38394242
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes that express an invariant T cell receptor α chain and contribute to bridging innate and acquired immunity with rapid production...
10.
Nonomiya Y, Nakayama I, Kobayashi K, Amakawa Y, Shibata N, Soejima A, et al.
Biol Pharm Bull
. 2024 Feb;
47(2):411-416.
PMID: 38346748
Trastuzumab deruxtecan (T-DXd) has displayed demonstrable efficacy and manageable toxicity in previously treated patients with advanced gastric and breast cancer, and it has been approved in Japan. However, there is...